Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).

Article  CAS  PubMed  Google Scholar 

Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644–657 (2017).

Article  CAS  PubMed  Google Scholar 

Wiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380, 347–357 (2019).

Article  CAS  PubMed  Google Scholar 

Bhatt, D. L. et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N. Engl. J. Med. 384, 129–139 (2021).

Article  CAS  PubMed  Google Scholar 

Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306 (2019).

Article  CAS  PubMed  Google Scholar 

The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 388, 117–127 (2023).

Article  Google Scholar 

Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436–1446 (2020).

Article  CAS  PubMed  Google Scholar 

Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413–1424 (2020).

Article  CAS  PubMed  Google Scholar 

Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451–1461 (2021).

Article  CAS  PubMed  Google Scholar 

Bhatt, D. L. et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N. Engl. J. Med. 384, 117–128 (2021).

Article  CAS  PubMed  Google Scholar 

McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381, 1995–2008 (2019).

Article  CAS  PubMed  Google Scholar 

Solomon, S. D. et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 387, 1089–1098 (2022).

Article  PubMed  Google Scholar 

Moon, J. S. et al. 2023 clinical practice guidelines for diabetes management in Korea: full version recommendation of the Korean Diabetes Association. Diabetes Metab. J. 48, 546–708 (2024).

Article  PubMed  PubMed Central  Google Scholar 

Shi, Q. et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 381, e074068 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cannon, C. P. et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N. Engl. J. Med. 383, 1425–1435 (2020).

Article  CAS  PubMed  Google Scholar 

Nassif, M. E. et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat. Med. 27, 1954–1960 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Filippatos, G. et al. Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes. Circulation 146, 676–686 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Usman, M. S. et al. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 12, 447–461 (2024).

Article  CAS  PubMed  Google Scholar 

Vallon, V. & Verma, S. Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annu. Rev. Physiol. 83, 503–528 (2021).

Article  CAS  PubMed  Google Scholar 

Ferrannini, E. Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metab. 26, 27–38 (2017).

Article  CAS  PubMed  Google Scholar 

Ferrannini, E. et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J. Clin. Invest. 124, 499–508 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Santos-Gallego, C. G. et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J. Am. Coll. Cardiol. 73, 1931–1944 (2019).

Article  CAS  PubMed  Google Scholar 

Lee, S. G. et al. Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling. BMC Med. 20, 309 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee, T. M., Chang, N. C. & Lin, S. Z. Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free. Radic. Biol. Med. 104, 298–310 (2017).

Article  CAS  PubMed  Google Scholar 

Lim, S., Oh, T. J., Dawson, J. & Sattar, N. Diabetes drugs and stroke risk: intensive versus conventional glucose-lowering strategies, and implications of recent cardiovascular outcome trials. Diabetes Obes. Metab. 22, 6–15 (2020).

Article  PubMed  Google Scholar 

Ahn, C. H. & Lim, S. Effects of thiazolidinedione and new antidiabetic agents on stroke. J. Stroke 21, 139–150 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Lim, S., Sohn, M. & Nauck, M. A. Cardiovascular outcome with SGLT2i and GLP1RA. Eur. J. Intern. Med. 129, 133–136 (2024).

Article  CAS  PubMed  Google Scholar 

Pasqualotto, E. et al. The effect of sodium-glucose transporter 2 inhibitors on stroke in patients with type 2 diabetes: a meta-analysis. J. Stroke Cerebrovasc. Dis. 33, 107730 (2024).

Article  PubMed  Google Scholar 

Tian, Q., Guo, K., Deng, J., Zhong, Y. & Yang, L. Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: a meta-analysis. J. Cell Mol. Med. 26, 540–547 (2022).

Article  CAS  PubMed  Google Scholar 

Katakami, N. et al. Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial. Cardiovasc. Diabetol. 20, 4 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rizos, E. C. et al. The effect of SGLT2 inhibitors and GLP1 receptor agonists on arterial stiffness: a meta-analysis of randomized controlled trials. J. Diabetes Complicat. 38, 108781 (2024).

Article  CAS  Google Scholar 

Akbari, A., Hadizadeh, S. & Heidary, L. Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on intima-media thickness: systematic review and meta-analysis. J. Diabetes Res. 2024, 3212795 (2024).

Article  PubMed  PubMed Central